Pharmaceutical group ยท Japan
Astellas
A group of 30 companies with 249 medicines in 10 countries.
Group structure
30 companies in 15 countries
Loadingโฆ
Pharmaceutical group ยท Japan
A group of 30 companies with 249 medicines in 10 countries.
30 companies in 15 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1โ25 of 249
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ADENOCARD3MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ยท Injectable | Adenosine | United States | Not marketed | 1989 |
| ADENOSCAN60MG/20ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 90MG/30ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ยท Solution | Adenosine | United States | Not marketed | 1995 |
| ADVAGRAF3 mg ยท Capsule (Extended-Release) | Tacrolimus | Canada | Marketed | 2010 |
| ADVAGRAF1 mg ยท Capsule (Extended-Release) | Tacrolimus | Canada | Marketed | 2008 |
| Advagraf | Tacrolimus | EU (EMA) | Authorised | 2007 |
| ADVAGRAF5 mg ยท Capsule (Extended-Release) | Tacrolimus | Canada | Marketed | 2008 |
| ADVAGRAF0.5 mg ยท Capsule (Extended-Release) | Tacrolimus | Canada | Marketed | 2008 |
| ADVAGRAF 0,5 MG CAPSULAS DURAS DE LIBERACION PROLONGADA0,5 mg ยท Cรกpsula dura de liberaciรณn prolongada | Tacrolimus | Spain | Marketed | 2012 |
| Advagraf 0,5 mg, capsules met verlengde afgifte, hardCapsule met verlengde afgifte, hard | Tacrolimus | Netherlands | Authorised | 2007 |
| ADVAGRAF 1 MG CAPSULAS DURAS DE LIBERACION PROLONGADA1 mg ยท Cรกpsula dura de liberaciรณn prolongada | Tacrolimus | Spain | Marketed | 2012 |
| ADVAGRAF 1 MG CAPSULAS DURAS DE LIBERACION PROLONGADA1 mg ยท Cรกpsula dura de liberaciรณn prolongada | Tacrolimus | Spain | Marketed | 2012 |
| Advagraf 1 mg, capules met verlengde afgifte, hardCapsule met verlengde afgifte, hard | Tacrolimus | Netherlands | Authorised | 2007 |
| ADVAGRAF 3 MG CAPSULAS DURAS DE LIBERACION PROLONGADA3 mg ยท Cรกpsula dura de liberaciรณn prolongada | Tacrolimus | Spain | Marketed | 2012 |
| Advagraf 3 mg, capsules met verlengde afgifte, hardCapsule met verlengde afgifte, hard | Tacrolimus | Netherlands | Authorised | 2009 |
| ADVAGRAF 5 MG CAPSULAS DURAS DE LIBERACION PROLONGADA5 mg ยท Cรกpsula dura de liberaciรณn prolongada | Tacrolimus | Spain | Marketed | 2012 |
| Advagraf 5 mg, capsules met verlengde afgifte, hardCapsule met verlengde afgifte, hard | Tacrolimus | Netherlands | Authorised | 2007 |
| Advagraf Prolonged Release Hard Capsules 0.5 mg0.5 mg ยท Capsule, extended release | Tacrolimus | Singapore | Authorised | 2012 |
| Advagraf Prolonged Release Hard Capsules 1 mg1.0 mg ยท Capsule, extended release | Tacrolimus | Singapore | Authorised | 2012 |
| Advagraf Prolonged Release Hard Capsules 5 mg5.0 mg ยท Capsule, extended release | Tacrolimus | Singapore | Authorised | 2012 |
| AMBISOME50 mg / vial ยท Powder For Solution | Amphotericin b | Canada | Marketed | 2000 |
| AMBISOME50mg/vial ยท Injectable, liposomal | Amphotericin b | United States | Marketed | 1997 |
| ARISTOCORT0.1% | 0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ยท Ointment | Triamcinolone | United States | Not marketed | 1972 |
| ARISTOCORT16mg | 1mg | 2mg | 4mg | 8mg ยท Tablet | Triamcinolone | United States | Not marketed | 1957 |
| ARISTOCORT0.025% | 0.1% | 0.5% ยท Cream | Triamcinolone | United States | Not marketed | 1972 |
| ARISTOCORT2mg/5ml ยท Syrup | Triamcinolone | United States | Not marketed | 1959 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 56 | 51 | 5 | CompaniesAll medicines |
| United States | 36 | 34 | 2 | CompaniesAll medicines |
| Netherlands | 34 | 34 | 0 | CompaniesAll medicines |
| Saudi Arabia | 25 | 25 | 0 | CompaniesAll medicines |
| Canada | 22 | 18 | 4 | CompaniesAll medicines |
| Singapore | 21 | 21 | 0 | CompaniesAll medicines |
| Romania | 20 | 0 | 20 | CompaniesAll medicines |
| Brazil | 13 | 10 | 3 | CompaniesAll medicines |
| European Union (EMA) | 13 | 9 | 4 | CompaniesAll medicines |
| Croatia | 9 | 9 | 0 | CompaniesAll medicines |
Also in the registers of Australia, Colombia, France, Italy, Malaysia, Serbia, Sweden, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la informaciรณn: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
ASIC,ASIC - Company Dataset,declared13October2026 extract,CC BY3.0 Australia,https://data.gov.au/data/dataset/asic-companies. Normalized and independently classified by Prognia;no endorsement.
Licence: Creative Commons Attribution 3.0 Australia
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licence: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Anvisa, https://dados.anvisa.gov.br/dados/CONSULTAS/EMPRESA_FISCALIZACAO_PRODUTO/TA_CONSULTA_CBPF_MEDICAMENTO_DETALHE.CSV; source modified Fri, 15 May 2026 07:52:35 GMT; acquired 2026-10-18T08:23:43.211112+00:00; original factual values retained, no endorsement.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Agรชncia Nacional de Vigilรขncia Sanitรกria (Anvisa), DATAVISA open-data register; source modification 2026-10-07, acquired 2026-10-07 UTC.
Licence: Brazil federal open-data reuse, Decreto 8777/2016, consolidated article 4 as amended by Decreto 9903/2019
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM renovacion; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes, dataset i7cb-raxc, rowsUpdatedAt 1792152574, acquired 2026-10-26; original values retained.
Licence: CC BY-SA 4.0
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
INSEE (www.insee.fr), via DINUM API Recherche dโentreprises; include original record update date and retrieval date
Licence: Licence Ouverte / Open Licence
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
National Pharmaceutical Regulatory Agency and Ministry of Health Malaysia, KKMNOW Approved Pharmaceutical Products, https://data.moh.gov.my/data-catalogue/pharmaceutical_products; CC BY 4.0; original data as of 2026-09-30 23:59; acquired 2026-10-16T22:34:39.948031+00:00; Prognia preserves original records and projects exact MAL IDs and category/role fields. No government endorsement implied.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0), exact MOH dataset dedication
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sฤnฤtฤศii, Catalogul public naลฃional al preลฃurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Oficiul Naศional al Registrului Comerศului; exact original source URLs, snapshot2026-09-02 where applicable, retrieval date, original record locators; https://creativecommons.org/licenses/by/4.0/
Licence: Creative Commons Attribution
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Lรคkemedelsverket, Sweden, Fรถrvaringstemperatur och hรฅllbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Lรคkemedelsverket, Sweden, Lรคkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Keep Astellasโs medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callWell-known pharmaceutical groups, each with all its companies.
Ranked by their number of medicines.